Measurement of Fibronectin in Human Body Fluids by Gómez-Lechón, Maria José & Castell, J. V.
Gomez-Lechon and Castell: Fibronectin in human body fhiids 333
J. Clin. Chem. Clin. Biochem.
Vol. 24, 1986, pp. 333-339
© 1986 Walter de Gruyter & Co.
Berlin · New York
Measurement of Fibronectin in Human Body Fluids
By Maria Jose Gomez-Lechon and /. V. Castell
Centro de Investigacion, Hospital La Fe, Ministerio de Sanidad, Valencia, Espana
(Received July 30, 1985/January 2, 1986)
Summary: Two facts must be taken into consideration when quantifying fibronectin in biological samples:
the sensitivity of the assay method and the appropiate handling of samples. A three-antibody, non-competitive
ELISA was used in the present study. This procedure offers a simple, inexpensive and very sensitive technique
for evaluating fibronectin: reproducible Standard curves in the ränge 5 — 100 g/l, 3% variability in the
assay, and a detection limit of 0.5 ng/well that allows accurate measurement of fibronectin in segmental
bronchoalveolar lavage and in ascites liquid samples. Typical dilution ranged from 1/10000 for plasma to
1/100 for bronchoalveolar lavages. For long-term storage of samples two procedures are recommended.
First, a rapid freezing with liquid nitrogen, storage at — 20 °C and thawing once at 37 °C avoiding re-
freezing. Losses of immunoreactive fibronectin after 35 days storage were 15, 15 and 22% in plasma,
bronchoalveolar lavages and ascites fluid, respectively. Alternatively, samples can be stored äs ammonium
sulphate precipitates. This allows the easy availability of the samples when assays have to be repeated, and
avoids fractionation in vials and freeze-thawing cycles. Using this storage procedure, losses are, however,
slightly higher (22, 25, 25%, respectively, after 35 days).
Bestimmung von Fibronectin in menschlichen Körperflüssigkeiten
Zusammenfassung: Zwei Tatsachen müssen bei der Bestimmung von Fibronectin in biologischen Flüssigkeiten
in Betracht gezogen werden: Die Empfindlichkeit der Bestimmungsmethode und die angemessene Handha-
bung der Proben. Ein drei Antikörper verwendender, nicht-kompetitiver ELISA wurde in der vorliegenden
Studie verwendet. Dieses Verfahren bietet eine einfache, billige und sehr empfindliche Technik für die
Fibronectinbestimmung: reproduzierbare Standardkurven im Bereich von 5 — 100 g/l, eine Impräzision von
3% und eine Nachweisgrenze von 0,5 ng im Ansatz, was eine genaue Messung von Fibronectin in Proben
von Ascitesflüssigkeit und bronchoalveolärer Waschflüssigkeit aus Lungensegmenten erlaubt. Die typische
Verdünnung lag zwischen 1/10000 für Plasma und 1/100 für bronchoalveoläre Waschflüssigkeit. Für die
Langzeitaufbewahrung von Proben werden zwei Verfahren empfohlen: 1. Schnelles Einfrieren mit flüssigem
Stickstoff, Aufbewahrung bei —20 °C und einmaliges Auftauen bei 37 °C, Vermeidung von erneutem Einfrie-
ren. Die Verluste von immunreaktivem Fibronectin nach 35 Tagen Lagerung betrugen hier 15,15 bzw. 22% in
Plasma, bronchoalveolärer Wäschflüssigkeit bzw. Ascites; 2. Aufbewahrung der Proben als Ammoniumsulfat-
Präzipitate; das erlaubt die einfache Verfügbarkeit der Proben, wenn Bestimmungen wiederholt werden
müssen, und vermeidet die Verteilung auf Probenbehälter sowie wiederholtes Einfrieren und Auftauen. Bei
Verwendung dieser Lagenmgsmethode sind die Verluste jedoch etwas höher (22, 25, 25% nach 35 Tagen).
troduction
 otjier extracellular matrix components, and äs
Fibronectin is a multifunctional and polymorphic a soluble form, present in plasma and other biological
glycoprotein found in two forms in living Organisms: fluids (l, 2). The protein mediates several functions,
äs a large insoluble aggregate that interacts strongly namely, cell attachment and spreading (3, 4), cellular
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morphology (5), wound healing processes (6, 7), non-
immune opsonization (8 — 10) and aging of tissues
(11). Since fibronectin is involved in many important
biological activities, its levels may have a potential
clinical value (12—21).
Two facts must be considered when quantifying fi-
bronectin in biological fluids. First, the characteristics
of a particular method; second, the correct handling
of the samples to be evaluated. Concerning the first
point, there have been reports on several methods
used to quantify sohible fibronectin. These methods
are based either on electroimmunoassays (22), immu-
nological precipitation (10), or turbidimetric
methods, i. e. laser nephelometry (23), radioimmuno-
assay (24), or competitive ELISA (25). Among the
described methods RIA is presumably the only one
with sufficient sensitivity to evaluate fibronectin in
biological fluids with low fibronectin Contents. This
requires the use of radiactive tracers which in the
case of fibronectin, is problematic (24). We developed
(26) a sensitive three-step non-competitive ELISA to
quantify animal fibronectins, which we have now
adapted for evaluating small amounts of fibronectin
in clinical samples.
The second factor of interest is that fibronectin is a
"sticks-to-all" protein, and its handling in the clinical
laboratory is critical. Significant losses of protein are
frequent during Isolation and storage of samples.
Both factors are important in the evaluation of fi-
bronectin in biological samples, and the existence of
contradictory data is probably directly related to
those two facts.
The aim of this study was to investigate the conditions
for sample collection and storage for the measure-
ment of fibronectin by ELISA in human biological
fluids.
Materials and Methods
Reagents
2,2/-Azino-di-(3-ethyl-benzthiazoline sulphonic acid (6))
(ABTS) was from Sigma. Horseradish peroxidase (EC 1.11.1.7)
was from Boehringer Mannheim. Heparin was from Rovi S. A.
(Madrid, Spain). Tween-20 was from Merck, (art. N° 822184).
Crystalline polystyrene microtiter plates for ßLISA were M-29
from Greiner. All other chemicals were of analytical grade.
Collection and storage of biological samples
Blood was drawn from healthy fasted individuals (n = 40) by
puncturing the radial vein. Three anticoagulants were used:
heparin, 25 lU/ml; trisodium citrate, 11 mmol/1; or EDTA, 62
mmol/1. Plasma was separated by centrifuging the blood, 10
min at 1500g at room temperature. Serum was obtained after
allowing blood to coagulate for 4 hours at room temperature
and centrifuging the clot 10 min at 1-500 £.
Segmental bronchoalveolar lavage was performed in 10 indivi-
duals who were in good health and showed no Symptoms
of respiratory disorders. The bronchoscope was wedged in a
subsegment of a lobe and 100 ml of warm sterile saline was
instilled in several portions and recovered by gentle aspiration.
The samples were put on ice and filtered through two layers
of surgical gauze, centrifuged to remoVe cells (20 min at 500 g)
and stored äs indicated below.
Ascites liquid was obtained from patients häving ascites by
intraperitoneal puncture and transferred to Containers for fufv
ther storage.
Aliquots of each sample were simuitaneously kept under dif-
ferent conditions:
a) in the cold at 4 °C with merthiolate 0.1 mg/1 or azide 0.2 g/l
äs preservative;
b) rapidly frozen (liquid N?) and stored at —20 °C;
c) precipitated with ammonium sulphate at 0.50 Saturation;
d) adsorbed onto micro ELISA plates and stored in the cold.
Frozen samples were thawed at 37 °C.
Preparation of fibronectin Standards and fibronec-
tin-free albumin
Human fibronectin was prepared by affinity chromatography
äs described (26) and stored in 2 mol/1 urea, l mol/1 NaCl at
—20 °C. When the stock solution pf fibroneetin was examined
using SDS polyacrylamide electrophoresis in the presence of
mercaptoethanol, it showed a single doublet (Mr 215000 and
220000), äs described (18). Under these conditions no signifi-
cant losses or degradation of fibronectin were observed after
one year. Fibronectin concentration was estimated either by
Lowry's method or by laser densitometry (LKB ULtroscan
2202) äs described (26). Fibronectin-free albumin was obtained
äs described (26).
Antisera
Sheep anti human fibronectin was produced in our laboratory
following conventional immunization schedules, although the
commercially available Boehringer antisera was equally suitable
for this assay. Rabbit anti sheep IgG's were obtained by immu-
nizing rabbits with pure sheep IgG's. Goat anti rabbit IgG was
obtained and tested äs described (26). Rabbit IgG's anti-sheep
IgG's were routinely immunoadsorbed against whole human
sera prepared by insolubilization of human plasma with 10%
fonnaldehyde. The IgG fraction of goat anti rabbit IgG was
labelled with horseradish peroxidase according to the two-
step procedure of Nakane & Kanewi (29) and assayed for its
suitability for use in ELISA.
ELISA prqcedure
All assays were run äs triplicates of two independent dilütions.
1) Fibronectin Standards and tests were conveniently diluted in
buffer A (sodium carbonate büffer 50 mmol/1, pH 9.6) contain-
ing 60 mg/1 of fibronectin-free albumin. Plasma düution was
1/6000 to 1/10000; 1/50 to 1/100 for segmental ..bronchoalveolar
lavage and 1/1000 to 1/2000 for ascites liquid. Düuted samples
(100 ) were allowed to adsorb for 30 min at 37 °C in a humid
incubator.
2) The antigen excess was poured off and the plates were
washed with buffer B (200 mmol/1 phosphate bufifer pH 7, 9 g/i
NaCl, l ml/l Tween-20). At this stage the plates were emptied
and, if not used immediately, they were stored at 4 °C without
measurable loss of antigenicity. Ten days was the longest storage
period tested.
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3) A volume of 100 μΐ of sheep anti-human fibronectin 1/6000
in buffer B was added to the wells and incubated at 37 °C for
l hour. Each sample had its own blank well where the first
antiserum was non-immune sheep IgG. After washing with
bufier B, wells were again incubated for 30 min at 37 °C with
100 ul of 1/2000 rabbit anti-sheep IgG diluted in buffer B.
4) Wells were incubated with peroxidase-labelled conjugate
(1/8000) for 30 min at 37 °C. Thereafter the plates were washed
and 100 μΐ of 0.2 mmol/1 ABTS, 2 mmol/1 H2O2 in citrate buffer
0.1 mol/1 pH 4.2 were added. The enzyme acitivty was measured
after incubation at 37 °C in a micro ELISA reader (MR 600
Dynatech Lab. Inc.) at 405 nm.
Results
Collection of samples for fibronectin deter-
mination
We undertook a series of experiments to establish the
conditions necessary to assure reproducible vahies of
fibronectin. In blood, fibronectin was estimated either
in serum or in the plasma of the same blood sample
treated with different anticoagulants. The measured
fibronectin content of serum was 19.66% + 5.58
(n = 40) lower than that of citrated plasma. No sig-
nificant differences were found between citrated and
EDTA plasma (less than 2%), but the values for
heparinized plasma were significantly lower (13.21%
± 4.63; n = 40). According to our experience, plastic
tubes are not appropiate sample Containers since fi-
bronectin is known to firmly attach to plastic surfaces
(26). Losses of 5 —10% are to be expected due to this
factor. The effect is even greater in samples containing
low arnounts of fibronectin like segmental bronchoal-
veolar lavage. Fibronectin losses were negligible when
Standard borosilicate glass Containers were used.
Storage of samples
A critical factor affecting the reproducibility of meas-
urements was the storage of samples. Since for practi-
cal reasons the measurement of fibronectin was not
usually performed on the day of sampling, we investi-
gated the effects that conventional storage procedures
could have on the fibronectin content of samples.
Aliquots of plasma, ascites liquid and segmental
bronchoalveolar lavage were stored under different
conditions and their fibronectin content was meas-
ured during 35 days. At the indicated dates the sam-
ples were titrated and their relative fibronectin con-
tent calculated in relation to their initial content.
As figure l a summarizes, there is a gradual loss of
fibronectin in frozen and in precipitated (2.1 mol/1
ammonium sulphate) plasma samples, decreasing to
80% of the initial content by day 35. However in
samples stored in the cold, their content quickly
dropped below 50% of the initial values.
Fibronectin losses in segmental bronchoalveolar lav-
age and in ascites liquid were very great in samples
stored in the cold. Their fibronectin content became
undetectable by day 10. In frozen and in precipitated
samples the values after 35 days were 75 — 85% of
initial values in segmental bronchoalveolar lavage
(fig. l a) and 75-80% in ascites fluid (fig. l c). The
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Fig. l. Measurable fibronectin after long-term storage of plasma samples, segmental bronchoalveolar lavages and ascites
Samples of citrated plasma (a, n = 40), bronchoalveolar lavage fluids (b, n = 10) or ascites fluid (c, n = 10), were
distributed in aliquots which were stored under various conditions:
1) freezing in liquid nitrogen and storage at —20 °C (o),
2) precipitated with 0.50 Saturation with ammonium sulphate (a), and
3) storage in the cold in presence of antimicrobials (·).
At different days samples were assayed for their fibronectin content, and the value was expressed s a fractton l the
content at day 0. The values in the figure represent the mean ± S. D. (p for all points ^0.005).
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losses of fibronectin in frozen samples after thawing
was also studied. The results showed that if samples
needed to be frozen, they should always be thawed
in a water bath at 37 °C. When thawing at room
temperature, we found a reduction of up to 20%
of the initial fibronectin content. Repeated freezing-
thawing, even with thawing at 37 °C, greatly reduced
the fibronectin content (50% after 5-cycles of freez-
ing-thawing), and therefore should be avoided.
In a third experiment, ELISA plates were coated
with the human sample the day they arrived at the
laboratory, then washed, stored in the cold, but not
taken through the rest of the Steps of ELISA until
several days later. In relation to their initial fibronec-
tin content, plates coated with plasma samples
(n = 10) on day 0 and processed on day 10 lost only
2.7 ± 2.2% of their immunoreactive fibronectin,
which was not statistically significant, whereas the
same samples, stored at -20°C during this period,
assayed on day 10, lost 4.1 ± 1.3%.
Titration curve: Sensitivity and precision
To measure fibronectin concentrations in samples the
values of absorbance of fibronectin Standards were
plotted in a semilog paper against the concentration
of fibronectin, and the linear regression of absorb-
ance against the log of concentration of fibronectin
was calculated. Excellent correlations were obtained
in the ränge of 0.5 — 10 ng of fibronectin per well
(r = 0.99). To assess the inter-assay reproducibility
of the data, several calibration curves were made with
fibronectin Standards. Figure 2 shows the mean ±
Standard deviation of six calibration lines each made
on a different day. The low deviation of values clearly
shows the high reproducibility pf this assay.
Fibronectin measurement in human plasma,
ascites and segmental bronchoälveolar lav-
age
To assess the internal accuracy of this method for
measuring fibronectin in human plasma, we per-
formed the following experiment: we first prepared
Standards of known concentrations of fibronectin
made up by diluting the appropiate amount of fi-
bronectin in fibronectin-free albümin. The same am-
ounts of fibronectin were added to a previously de-
fibronectized human plasma. These plasma Standards
were processed and assayed at two different dilutions
0/4000 and Y6000) by ELISA to estimate their fi-
bronectin content. The results obtained are repre*
sented in figure 3. There is a small underestimate of
fibronectin content in plasma in relation to pure
fibronectin Standards, which is slightly greater when
plasma is assayed at a dilution V^OOO insteäd of a
dilution Y6000. To assess intra-assay specificity and
reproducibility, we measured a patieiit's plasma sam-
ple 10 times, making a new dilution each time and
doing triplicate assays for each dilution. The variabik
ity in the absorbance readings were quite low (0.572
± 0.017, n = 30, 3% error). The limit of sensitivity
of the technique was estijnated by determining the
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Fig. 2. Non-competitive, indirect ELISA for fibronectin measurement,
 ostandard curve
Samples of 100 in buffer A containing variable amounts of fibronectin were allowed to adsorb onto the plastic of a
microtiter plate. After washing and completing the Steps of the ELISA, äs reported in Materials and Methode, the final
colour absorbance was plotted against the fibronectin content of the samples. Values denote'the mean ± S.D. of six
different curves made at different days.
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Fig. 3. Titration curves for fibronectin
To assess the linearity and reproducibility of the method
for quantifying plasma fibronectin, increasing known
amounts of fibronectin were diluted in buffer A contain-
ing 60 mg/1 of fibronectin-free albumin (o), or added
to human plasma that had been previously de-fibronec-
tinized. These were handled s routine samples, and
their fibronectin content was measured by ELISA. The
plasma was assayed at two different dilutions, Y4000
(a) and V6000 (o). The results represent the colour
absorbance after completing the ELISA in relation to
the fibronectin present in samples.
smallest ainount of fibronectin which gave an absorb-
ance value significantly different from the blank. We
used the t-test and analysed 20 negative controls and
20 positive samples. The lowest measurable concen-
tration with this assay was 5μg/l (0.5 ng/well),
p < 0.01.
We also studied the effects of dysproteinaemia and
hyperlipaemia on the accuracy of the method. To
evaluate possible interference from variable concen-
tr tions of total protein in individual samples, bind-
ing of fibronectin t the microplate was studied using
a constant fibronectin concentration (250 μg/l) and
variable amounts of fibronectin-free albumin s ex-
ternal protein source (0 — 10 mg/1). The results
showed no appreciable effects on the accuracy of
fibronectin estimation over a wide r nge of external
protein concentrations. The protein present in plasma
samples at the dilution used in the assay
0/6000-VI0000, 1-0.6 μ^βΠ) did not interfere
with the binding of fibronectin.
The possible effects of lipids on the estimates of
plasma fibronectin were followed in 10 healthy
human fasted volunteers. Blood was obtained and
each volunteer received 150 ml of double-cream
strawberry shake. After 120 min a blood sample was
obtained and cholesterol, triacylglycerol and fi-
bronectin were measured before and after the inges-
tion. The results presented in table l show that in-
duced hyperlipaemia did not interfere with the fi-
bronectin estimate in spite of the great variations in
plasma lipids. Subject 9 had 1780 mg/1 triacylglycerol
before the experiment and 4220 mg/1 afterwards, i. e.
a 58% increase. However, fibronectin only varied by
+ 3%. In another case the effect was opposite; in
subject 2, triacylglycerol before the experiment was
1040 mg/1, and afterwards it was 2000 mg/1, i. e. a
48% increase; fibronectin varied by —6%. In others,
(subject l, triacylglycerol before: 1100 mg/1, after:
1860 mg/1; an increase of 41%) fibronectin did not
change significantly (—0.01%). The mean of the vari-
ations is not significant and falls within the error of
the method.
We also compared the results obtained with this pro-
cedure with literature values (tab. 2). Plasma of 40
healthy individuals, 10 healthy segmental bronchoal-
veolar lavages and 35 ascites of hepatic cirrhosis were
studied. This ELISA, because of its sensitivity, could
be used to evaluate fibronectin in segmental bron-
choalveolar lavage and in ascites liquid.
Tab 1. The effect of hyperlipaemia on the estimate of plasma fibronectin.
Subject Fn*) after^Fn*) before
Fn*) before
Cholesterol (mg/1)
before after
lipid ingestion
Triacylglycerol (mg/1)
before after
lipid ingestion
1
2 '
3
4
5
6
7
8
9
10
+ 0.01 ns
-6 ns
Φ 5 ns
·=- 6 ns
+ 3 ns
+ 5 ns
-h 1.5 ns
— 8 ns
Φ 3 ns
-7 ns
2300
2060
1940
2040
2940
1420
2220
2530
2740
1440
2640ns
1990ns
1900ns
2030 ns
2500 ns
1630ns
2190 ns
2750 ns
2700 ns
1430 ns
1100
1040
860
1120
1160
700
1200
1260
1780
820
1860
2000
1500
2020
2740
1620
2360
2040
4220
1800
*) Fn = fibronectin
Cholesterol, triacylglycerol (chylomicrons) and fibronectin were measured in the plasma of 10 healthy fasted volunteers before
and 120 minutes after ingestion of 150 ml of double-cream. Fibronectin results are expressed s mean Variation of the
independent determinations, each one in triplicate, and analysed by the Student'* t-test.
ns = no significative
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Tab. 2. Fibronectin measurement in biological samples.
Samples
Human plasma
Human ascites fluid
This assay
(mean ± SD)
264 + 65 mg/1
.(n = 40)
19.8 ± 7.7 mg/1
95% Confidence
interval
243 -285 mg/1
17.2- 22.4 mg/1
Literature
references
345 ± 68
303 · '± 56
353 ± 82
8.3 ± 15.3
mg/1
mg/1
mg/1
mg/1
(37)
(38)
(30)
(39)
(hepatic cirrhosis)
Human bronchoalveolar lavages
(n = 35)
9.6 ±
(n = 10)
5.5- 13^g/mg*) 2.7 ± 1.1 (40)
*) § of fibronectin per mg of total protein in the sample.
Discussion
Sample collection is one of the factors influencing
the quality of the data. There is significantly less
fibronectin in serum than in plasma, because variable
amounts of fibronectin are cross-linked to the fibrin
by factor XIII during coagulation (30). We confirmed
the results of Bowen et al. in the sense that citrate
and EDTA gave the best results. Although plastic
tubes have been recommended for plasma collection
(31), our own experience and that recently pointed
out by other authors (32) indicate that it should be
avoided and that Standard borosilicate tubes must be
used.
The storage of samples also plays an important role.
Fibronectin, fonnerly known äs "cold insoluble glo-
bulin" (l, 27), precipitates in the cold together with
fibrinogen and fibrinopeptides (33). Some authors
reported that it could be stored at 4 °C for short
periods (32). However, in our experience this proce-
dure is not recommendable since very important
losses occurred. We have alternatively assayed three
different procedures:
1) freezing in N2 and storage at — 20 °C;
2) precipitation with 2.1 mol/1 ammonium sulphate
and
3) adsorption onto micro ELISA plates and storage
in the cold.
The storage of samples äs an ammonium sulphate
precipitate was of practical use in samples containing
large amounts of protein. It gives a fine and homoge-
neous precipitate that can be easily resuspended, and
in which fibronectin remains well preserved. In low
protein-content precipitated samples the losses of fi-
bronectin are larger. The adsorption of samples onto
plates for later estimates of fibronectin also gave
results that did not differ from those obtained with
frozen samples. Thawing is also critical and should
be performed at 37 °C. Samples should not be refro-
zen. This contrasts with pfevious reports (30) and
should be considered if the sample has to be re-
assayed, Under optimal conditions (—20 °C), plasma
samples lost only 15% of theif initial fibronectin
content after 35 days. The loss in ammonium sulphate
precipitated samples was only slightly greater than
in frozen samples (fig. l a). This disadvantage was
counteracted by the simplicity of the precipitation
procedure, the ease of transport and the possibility
of taking several aliquots without having to thaw a
vial each time.
In segmental bronchoalveolar lavage and in ascites
fluid, losses of fibronectin in samples stored in the
cold were so great that only the other two procedures
could be considered. Losses are similar to thpse found
in plasma samples (fig. l b, c). In both cases frozen
samples retained higher amounts of immünoreactive
fibronectin. However, the simplicity of the ammo-
nium sulphate precipitation often made it the most
recommendable procedure for the storage and trans-
port of samples from the hospital to this laboratory.
Among several procedures tested for long-term stor-
age of fibronectin Standards, the best results were
obtained when fibronectin was frozen (—20 °C) in
2 mol/1 urea, l mol/1 NaCl. We found no degradation
or protein losses after one-year storage (data not
shown).
The ELISA we used in this work is linear in the ränge
of 5 —10 g/l and has a limit of detection of 5 £/1,
which is comparable to l g/l reported for RIA (24,
35), and hundreds of tirnes more sensitive than other
reported immunological methods (17, 32, .36, 37); it
thus allows the easy measurement of fibronectin in
ascites and segmental bronchoalveolar lavage. Intra-
assay error is less than 3% when care is taken during
pipetting and diluting of samples. The small differ-
ences (10 — 15%) in the fibronectin content of plasma
samples when values are calculated against either a
pure fibronectin Standard curve or a plasma Standard
curve, (fig. 3) are due to the short incubation times
used in the assay (30 min), which do not allow 100%
adsorptiön of fibronectin (26) and are minimized
when adsorption of samples is £roloriged for several
hours.
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Changes in the protein content of plasma have no
effect on the accuracy of estimates, since samples are
diluted in fibronectin-free albumin at a final concen-
tration of 6 μg/well and the plasma sample only con-
tributes 0.6 to l μ§/ννβ11. In plasma with a lower
protein concentration this contribution may be lower
and, therefore, according to previous results (26), the
absorption of fibronectin to plastic will be the same.
The presence of triacylglycerol and cholesterol (chy-
lomicrons) did not appreciably interfere with the fi-
bronectin estimate. The experiment summarized in
table l analysed 10 cases and, although the lipid
Variation in each individual before and after the inges-
tion of cream varied greatly, the fibronectin content
did not change during the experiment.
The values we obtained in plasma are in agreement
with those previously reported and assayed by other
methods, (tab. 2). However our data for fibronectin
in ascites and segmental bronchoalveolar lavage are
slightly higher but with lower S.D., a fact that is
probably related to the greater sensitivity of the EL-
ISA.
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